RE:RE:RE:Gone for 2 weeksCan't argue with your points. We need a new era of transparency as we should not be guessing what actual revenues are on our cancer products and number of covid tests being completed. Investors are tired of statements like - "we have the capacity to conduct 1000 tests". There are simply too many questions/uncertainties at the moment around Ichor/Mercer/CARE/LOI/Aristotle/Oncore for investors to feel good - just read this board. The fact that the sp is now in the low 60s is reflective of all of this.
We seem to be in another NR lull here, despite promises to keep us updated more. If we are to succeed and achieve investor confidence leading to buy in again, both institutional and retail will need to be more appeased and provided with specifics - that can only come from corporate.
The criticism against Rebecca is overstated in my opinion. She is swamped with E mails and trying to respond to what she can. The problem is that she is under strict control and undoubtedly her responses are closely vetted.
IainCaimbeul wrote: Liked2think: This is a side play for me, I bought 80% pre-RS so I don't feel the searing pain you do.
I am extremely annoyed at Stage for the mickey mouse rollout of aristotle and the CC.
The state of the current stock price is friendly fire, entirely self-inflicted by Stage management.
I would like to see one simple line on a financial sheet that shows:
colonsentry revenues: $$$$$.$$
aristotle revenues: $$$$$.$$
But no, heaven forbid some real dsiclosure.